Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has been assigned a consensus recommendation of “Hold” from the ten research firms that are currently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $5.08.

Several equities analysts have recently commented on TNDM shares. B. Riley cut shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and lowered their price target for the company from $5.00 to $1.50 in a report on Friday, March 24th. Piper Jaffray Companies restated a “neutral” rating on shares of Tandem Diabetes Care in a report on Thursday, March 30th. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Tandem Diabetes Care in a report on Thursday, March 30th. Finally, Cowen and Company cut shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and set a $1.50 price target on the stock. in a report on Monday, April 10th.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/tandem-diabetes-care-inc-nasdaqtndm-receives-consensus-recommendation-of-hold-from-brokerages/1444707.html.

A number of large investors have recently modified their holdings of TNDM. Iguana Healthcare Management LLC boosted its stake in shares of Tandem Diabetes Care by 33.3% in the first quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the medical device company’s stock worth $120,000 after buying an additional 25,000 shares in the last quarter. Paulson & CO. Inc. purchased a new position in Tandem Diabetes Care during the first quarter worth $600,000. Bank of America Corp DE raised its position in Tandem Diabetes Care by 88.6% in the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after buying an additional 404,452 shares in the last quarter. Monashee Investment Management LLC purchased a new position in Tandem Diabetes Care during the first quarter worth $180,000. Finally, Group One Trading L.P. purchased a new position in Tandem Diabetes Care during the first quarter worth $185,000. Hedge funds and other institutional investors own 45.77% of the company’s stock.

Shares of Tandem Diabetes Care (TNDM) opened at 0.57 on Monday. The firm’s market cap is $28.41 million. Tandem Diabetes Care has a 12-month low of $0.56 and a 12-month high of $8.81. The stock’s 50 day moving average price is $0.84 and its 200 day moving average price is $1.63.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, April 27th. The medical device company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.09. Tandem Diabetes Care had a negative net margin of 104.31% and a negative return on equity of 1,177.11%. The company had revenue of $17.50 million for the quarter, compared to analysts’ expectations of $15.72 million. During the same quarter in the prior year, the firm earned ($0.68) earnings per share. The company’s revenue was down 12.9% on a year-over-year basis. On average, equities research analysts predict that Tandem Diabetes Care will post ($1.88) EPS for the current fiscal year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.